103502-48-3

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-bromoquinoline-4-carboxylate is used as a key intermediate in the synthesis of various pharmaceuticals for its versatile chemical properties and potential therapeutic applications.
Used in Agrochemical Industry:
Methyl 2-bromoquinoline-4-carboxylate serves as a building block in the development of agrochemicals, contributing to the creation of effective pesticides and other agricultural products to protect crops and enhance yield.
Used in Dye Industry:
Methyl 2-bromoquinoline-4-carboxylate is utilized as a precursor in the production of dyes, taking advantage of its aromatic structure to create a range of colorants for various applications.
Used in Organic Synthesis:
As a versatile building block, Methyl 2-bromoquinoline-4-carboxylate is employed in organic synthesis for the creation of complex organic molecules, including those with potential applications in material science and specialty chemicals.

Upstream product

• 15733-89-8 2-hydroxyquinoline-4-carboxylic acid 
• 39497-01-3 methyl 2-hydroxyquinoline-4-carboxylate 
• 39497-01-3 methyl 1,2-dihydro-2-oxoquinoline-4-carboxylate 

Downstream Products

• 1354965-40-4 methyl 2-(4-phenyl-1H-1,2,3-triazol-1-yl)quinoline-4-carboxylate 
• 1354965-42-6 2-(4-phenyl-1H-1,2,3-triazol-1-yl)quinoline-4-carboxylic acid 
• 15733-87-6 2-bromoquinoline-4-carboxylic acid 

Relevant academic research and scientific papers

COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION

Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein.

RENIN INHIBITORS

Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency, wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R1 is hydrogen, C1-6 -alkyl or C3-6 -cycloalkyl, wherein said C1-6 -alkyl or C3-6 -cycloalkyl group can be independently substituted with 1-3 halogens; A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to another five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is a bond or -(C=O)-, -CH(OH)-, -CH2- or =CH-; U is a bond or -CH2-, or for the case when V is =CH-, U is -CH=; X is =CH-, =CF-, =C(OR3)-, or -C=O-; and Y is =CH-, =CF-, =N-, or for the case when X is -C=O-, Y is -N(R3)-.

Antiinflammation agents

Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic and cell proliferative conditions or diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism and cell proliferation. The subject compounds contain fused carbocyclic or heterocyclic rings.